A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:10327-10328
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Juckett Mark¹,Mailankody Sham²,Eghtedar Alireza³,Bickers Cara⁴,Zong Xingyue⁴,Wong Lilly⁴,Ly Thomas⁴,Byon John⁴,Cooley Sarah⁴,Valamehr Bahram⁴,Chu Yu-Waye⁴,Vij Ravi⁵

Affiliation:

1. 1Masonic Cancer Center, University of Minnesota, Minneapolis, MN

2. 2Memorial Sloan Kettering Cancer Center, New York, NY

3. 3Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO

4. 4Fate Therapeutics, Inc., San Diego, CA

5. 5Siteman Cancer Center, Washington University, St Louis, MO

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy;Pharmaceutics;2024-08-29

2. Advancing Cancer Immune Cell Therapies via Engineered iPSC-Based Strategies;Interdisciplinary Cancer Research;2024

3. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future;International Journal of Molecular Sciences;2023-10-27

4. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond;Frontiers in Immunology;2023-07-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP